- Home
- MBBC vs INKT Comparison
MBBC vs INKT Comparison
Compare MBBC & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- INKT
- Stock Information
- Founded
- MBBC 1902
- INKT 2017
- Country
- MBBC United States
- INKT United States
- Employees
- MBBC N/A
- INKT N/A
- Industry
- MBBC Banks
- INKT Medicinal Chemicals and Botanical Products
- Sector
- MBBC Finance
- INKT Health Care
- Exchange
- MBBC Nasdaq
- INKT Nasdaq
- Market Cap
- MBBC 29.3M
- INKT 28.9M
- IPO Year
- MBBC N/A
- INKT 2021
- Fundamental
- Price
- MBBC $9.99
- INKT $7.17
- Analyst Decision
- MBBC
- INKT Strong Buy
- Analyst Count
- MBBC 0
- INKT 2
- Target Price
- MBBC N/A
- INKT $37.50
- AVG Volume (30 Days)
- MBBC 10.6K
- INKT 14.8K
- Earning Date
- MBBC 08-22-2025
- INKT 08-12-2025
- Dividend Yield
- MBBC N/A
- INKT N/A
- EPS Growth
- MBBC 103.56
- INKT N/A
- EPS
- MBBC 0.22
- INKT N/A
- Revenue
- MBBC $6,591,743.00
- INKT N/A
- Revenue This Year
- MBBC N/A
- INKT N/A
- Revenue Next Year
- MBBC N/A
- INKT N/A
- P/E Ratio
- MBBC $45.40
- INKT N/A
- Revenue Growth
- MBBC N/A
- INKT N/A
- 52 Week Low
- MBBC $6.38
- INKT $4.56
- 52 Week High
- MBBC $12.00
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- INKT 46.30
- Support Level
- MBBC N/A
- INKT $6.91
- Resistance Level
- MBBC N/A
- INKT $7.51
- Average True Range (ATR)
- MBBC 0.00
- INKT 0.28
- MACD
- MBBC 0.00
- INKT -0.01
- Stochastic Oscillator
- MBBC 0.00
- INKT 17.57
About MBBC Marathon Bancorp Inc. Common Stock
Marathon Bancorp Inc is a Wisconsin-chartered savings bank. It is a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the Company's revenues come from interest income on loans and debt securities.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.